Skip to content

Analysis of the Efficacy of Conbercept in Treating Macular Neovascularization of Different nAMD Subtypes Based on OCTA Evaluation

Analysis of the Efficacy of Conbercept in Treating Macular Neovascularization of Different nAMD Subtypes Based on OCTA Evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110978
Enrollment
Unknown
Registered
2025-10-23
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular Age-Related Macular Degeneration

Interventions

Group MNV-1:Intravitreal injection of conbercept
Group MNV-2:Intravitreal injection of conbercept
Group MNV-3:Intravitreal injection of conbercept

Sponsors

Nanchong Hospital , Affiliated to Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Diagnosis of type 1, 2, and 3 MNV confirmed by OCTA/OCT, in accordance with international nAMD diagnostic criteria. 2.Presence of active disease, as evidenced by subretinal/intraretinal fluid or hemorrhage on OCT. 3.Treatment with a single, exclusive anti-VEGF agent (conbercept) via intravitreal injection at the hospital. 4.All patients were treatment-naïve.

Exclusion criteria

Exclusion criteria: 1.Ocular Conditions:Maculopathy from causes other than MNV: pathologic myopia, traumatic CNV, angioid streaks, central serous chorioretinopathy.Advanced irreversible damage: Extensive macular atrophy or fibrosis, disruption of outer retinal layers on OCT, significant vitreous hemorrhage, or cataract affecting OCTA image quality.Other fundus diseases: Coexisting diabetic retinopathy (with DME), retinal vein occlusion (RVO), glaucoma (cup-to-disc ratio > 0.8), or optic neuropathy. 2.Systemic Conditions:Systemic health risks: Uncontrolled hypertension (>160/100 mmHg), diabetes mellitus (HbA1c > 8%), or a recent (within 6 months) cardiocerebrovascular event (e.g., myocardial infarction, stroke). 3.Drug Contraindications or Allergies:Allergy to conbercept or any component of anti-VEGF drugs.Long-term use of anticoagulant therapy (e.g., warfarin) with an INR > 3.0. 4.Treatment History:Recent ocular treatments: Previous vitrectomy, macular laser, or PDT therapy within 3 months. 5. Pregnancy or Lactation.

Design outcomes

Primary

MeasureTime frame
CMT;

Secondary

MeasureTime frame
SCP-VD;

Countries

China

Contacts

Public ContactXiaoli Yang

Nanchong Hospital, Affiliated to Beijing Anzhen Hospital, Capital Medical University

yangxiaolioculist@163.com+86 139 9081 1357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026